The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.
Open accessAbstract
Aberrant expression of transforming growth factor beta 1 (TGF-beta 1) has been implicated in a number of disease processes, particularly those involving fibrotic and inflammatory lesions. To determine the in vivo effects of overexpression of TGF-beta 1 on the function and structure of hepatic as well as extrahepatic tissues, transgenic mice were generated containing a fusion gene (Alb/TGF-beta 1) consisting of modified porcine TGF-beta 1 cDNA under the control of the regulatory elements of the mouse albumin gene. Five transgenic lines were developed, all of which expressed the Alb/TGF-beta 1 transgene selectively in hepatocytes. The transgenic line 25 expressing the highest level of the transgene in the liver also had high (> 10-fold over control) plasma levels of TGF-beta 1. Hepatic fibrosis and apoptotic death of hepatocytes developed in all the transgenic lines but was more pronounced in line 25. The fibrotic process was characterized by deposition of collagen around individual hepatocytes and within the space of Disse in a radiating linear pattern. Several extrahepatic lesions developed in line 25, including glomerulonephritis and renal failure, arteritis and myocarditis, as well as atrophic changes in pancreas and testis. The results from this transgenic model strongly support the proposed etiological role for TGF-beta 1 in a variety of fibrotic and inflammatory disorders. The transgenic model may also provide an appropriate paradigm for testing therapeutic interventions aimed at neutralizing the detrimental effects of this important cytokine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,751
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
The Transforming Growth Factor-beta Family
Massague, J. (1990) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.06.110190.003121 · Cited by 3,015
Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., & Sporn, M. B. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32345-7 · Cited by 1,598
Self-citationExpression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase
Lin, H. Y., Wang, X.-F., Ng-Eaton, E., Weinberg, R. A., & Lodish, H. F. (1992) · Cell · doi:10.1016/0092-8674(92)90152-3 · Cited by 1,057
TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights
Moses, H. L., Yang, E. Y., & Pietenpol, J. A. (1990) · Cell · doi:10.1016/0092-8674(90)90155-8 · Cited by 959
Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)
Roberts, A. B., & Sporn, M. B. (1993) · Growth Factors · doi:10.3109/08977199309029129 · Cited by 755
Self-citationMechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
Lyons, R. M., Gentry, L. E., Purchio, A. F., & Moses, H. L. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.4.1361 · Cited by 737
Oberhammer, F. A., Pavelka, M., Sharma, S., Tiefenbacher, R., Purchio, A. F., Bursch, W., & Schulte-Hermann, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5408 · Cited by 668
Transforming Growth Factors β1 and α in Chronic Liver Disease: Effects of Interferon Alfa Therapy
Castilla, A., Prieto, J., & Fausto, N. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241401 · Cited by 655
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Michalopoulos, G. K., & DeFrances, M. C. (1997) · Science · doi:10.1126/science.276.5309.60 · Cited by 2,828
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Michalopoulos, G. K. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21172 · Cited by 1,384
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K., & Kitani, A. (2006) · Nature Medicine · doi:10.1038/nm1332 · Cited by 889
Roles of TGF-beta in hepatic fibrosis
Gressner, A. M. (2002) · Frontiers in Bioscience · doi:10.2741/a812 · Cited by 783
Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
Pepper, M. S. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00048-2 · Cited by 724
Gressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718
Liver Regeneration after Partial Hepatectomy
Michalopoulos, G. K. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090675 · Cited by 713
TGF-ß Signaling in Renal Disease
Bo[Combining Diaeresis]ttinger, E. P., & Bitzer, M. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000033611.79556.ae · Cited by 711
TGF-β/Smad signaling in renal fibrosis
Meng, X.-M., Tang, P. M.-K., Li, J., & Lan, H. Y. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00082 · Cited by 666
TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?
Martin, M., Lefaix, J.-L., & Delanian, S. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00435-1 · Cited by 657
Apoptosis and acute kidney injury
Havasi, A., & Borkan, S. C. (2011) · Kidney International · doi:10.1038/ki.2011.120 · Cited by 653
Diverse Roles of TGF-β/Smads in Renal Fibrosis and Inflammation
Lan, H. Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.1056 · Cited by 652
Molecular insights into renal interstitial fibrosis.
Eddy, A. A. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7122495 · Cited by 637
Transforming growth factor βs and wound healing
O'Kane, S., & Ferguson, M. W. J. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00120-3 · Cited by 634
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
Ueki, T., Kaneda, Y., Tsutsui, H., Nakanishi, K., Sawa, Y., Morishita, R., Matsumoto, K., Nakamura, T., Takahashi, H., Okamoto, E., et al. (1999) · Nature Medicine · doi:10.1038/5593 · Cited by 587
Drug-induced acute interstitial nephritis
Rossert, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060002804.x · Cited by 488
Oxidative stress and glutathione in TGF-β-mediated fibrogenesis
Liu, R.-M., & Gaston Pravia, K. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.026 · Cited by 469
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Border, W. A., & Noble, N. A. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.181 · Cited by 447
Chen, M. M., Lam, A., Abraham, J. A., Schreiner, G. F., & Joly, A. H. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1215 · Cited by 442
Activation of hepatic stellate cells - a key issue in liver fibrosis
Reeves, H. (2002) · Frontiers in Bioscience · doi:10.2741/reeves · Cited by 423
Expression of transforming growth factor-β isoforms in human glomerular diseases
Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A. (1996) · Kidney International · doi:10.1038/ki.1996.65 · Cited by 418
Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., & Terano, A. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01083.x · Cited by 408
Leptin is essential for the hepatic fibrogenic response to chronic liver injury
Leclercq, I. A., Farrell, G. C., Schriemer, R., & Robertson, G. R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00102-2 · Cited by 407
Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins
Robertson, I. B., & Rifkin, D. B. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021907 · Cited by 403
Roles of TGF-beta in hepatic fibrosis
Gressner, A. (2002) · Frontiers in Bioscience · doi:10.2741/gressner · Cited by 405
The role of TGFβ1 in initiating hepatic stellate cell activation in vivo
Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80010-5 · Cited by 393
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Experimental mouse models for hepatocellular carcinoma research
Heindryckx, F., Colle, I., & Van Vlierberghe, H. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00656.x · Cited by 367
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Genetic Polymorphisms and the Progression of Liver Fibrosis: A Critical Appraisal
Bataller, R., North, K. E., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50127 · Cited by 355
Role of the TGF-β/BMP-7/Smad pathways in renal diseases
Meng, X.-M., Chung, A. C. K., & Lan, H. Y. (2013) · Clinical Science · doi:10.1042/cs20120252 · Cited by 354
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
Matsumoto, K., & Nakamura, T. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00717.x · Cited by 353
Lesions of Aryl-hydrocarbon Receptor–deficient Mice
Fernandez-Salguero, P. M., Ward, J. M., Sundberg, J. P., & Gonzalez, F. J. (1997) · Veterinary Pathology · doi:10.1177/030098589703400609 · Cited by 352
TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation
Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F., & Weinberg, R. A. (2001) · Nature Cell Biology · doi:10.1038/35087019 · Cited by 349
Transforming growth factor β and the liver
Bissell, M. D., Roulot, D., & George, J. (2001) · Hepatology · doi:10.1053/jhep.2001.28457 · Cited by 348
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339
Liver fibrosis: from the bench to clinical targets
Pinzani, M., & Rombouts, K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.003 · Cited by 336
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
Campbell, J. S., Hughes, S. D., Gilbertson, D. G., Palmer, T. E., Holdren, M. S., Haran, A. C., Odell, M. M., Bauer, R. L., Ren, H.-P., Haugen, H. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409722102 · Cited by 333
The reactive stroma microenvironment and prostate cancer progression
Barron, D. A., & Rowley, D. R. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0085 · Cited by 329
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
George, J., Roulot, D., Koteliansky, V. E., & Bissell, D. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12719 · Cited by 322
GENETIC SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS
Vyse, T. J., & Kotzin, B. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.261 · Cited by 313
Gnessi, L., Fabbri, A., & Spera, G. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0310 · Cited by 306
Rosenkranz, S., Flesch, M., Amann, K., Haeuseler, C., Kilter, H., Seeland, U., Schlüter, K.-D., & Böhm, M. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00578.2001 · Cited by 300
Ikejima, K., Honda, H., Yoshikawa, M., Hirose, M., Kitamura, T., Takei, Y., & Sato, N. (2001) · Hepatology · doi:10.1053/jhep.2001.26518 · Cited by 288
Clouthier, D. E., Comerford, S. A., & Hammer, R. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119815 · Cited by 282
Dooley, S., Hamzavi, J., Ciuclan, L., Godoy, P., Ilkavets, I., Ehnert, S., Ueberham, E., Gebhardt, R., Kanzler, S., Geier, A., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.038 · Cited by 281
Hepatic stellate cells: a target for the treatment of liver fibrosis
Wu, J., & Zern, M. A. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070045 · Cited by 273
TGF‐β Latency: Biological Significance and Mechanisms of Activation
Gleizes, P., Munger, J. S., Nunes, I., Harpel, J. G., Mazzieri, R., Noguera, I., & Rifkin, D. B. (1997) · STEM CELLS · doi:10.1002/stem.150190 · Cited by 266
McCormick, L. L., Zhang, Y., Tootell, E., & Gilliam, A. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5693 · Cited by 265
Role of hydrogen peroxide and oxidative stress in healing responses
Rojkind, M., Domínguez-Rosales, J.-A., Nieto, N., & Greenwel, P. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012511 · Cited by 265
Lee, K., Villena, J. A., Moon, Y. S., Kim, K.-H., Lee, S., Kang, C., & Sul, H. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15924 · Cited by 264
Wallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
Yoo, J., Ghiassi, M., Jirmanova, L., Balliet, A. G., Hoffman, B., Fornace, A. J., Liebermann, D. A., Böttinger, E. P., & Roberts, A. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307869200 · Cited by 261
Self-citationThe Role of Smad3 in Mediating Mouse Hepatic Stellate Cell Activation
Schnabl, B., Kweon, Y. O., Frederick, J. P., Wang, X.-F., Rippe, R. A., & Brenner, D. A. (2001) · Hepatology · doi:10.1053/jhep.2001.25349 · Cited by 258
Chambers, R. C., Leoni, P., Kaminski, N., Laurent, G. J., & Heller, R. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63847-3 · Cited by 255
Yoshiji, H., Kuriyama, S., Miyamoto, Y., Thorgeirsson, U. P., Gomez, D. E., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Tsujinoue, H., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.20521 · Cited by 252
Self-citationSchledzewski, K., Géraud, C., Arnold, B., Wang, S., Gröne, H.-J., Kempf, T., Wollert, K. C., Straub, B. K., Schirmacher, P., Demory, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44740 · Cited by 154
Cherry, C., Andorko, J. I., Krishnan, K., Mejías, J. C., Nguyen, H. H., Stivers, K. B., Gray-Gaillard, E. F., Ruta, A., Han, J., Hamada, N., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00785-7 · Cited by 66
Okamura, T., Yamamoto, K., & Fujio, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00340 · Cited by 41
“The isotype specific production of TGF-β might be advantage of Egr2-expressing LAG3+ Tregs for therapeutic approach, because TGF-β1, but not TGF-β3, promotes fibrosis (107, 108).”
BackgroundPaladino, N., Flores, A. C., Fainboim, H., Schroder, T., Cuarterolo, M., Lezama, C., Ballerga, E. G., Levi, D., Tanno, H., Costanzo, G., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.11.004 · Cited by 32
Knockdown of miR-23, miR-27, and miR-24 alters fetal liver development and blocks fibrosis in mice
Rogler, C. E., Matarlo, J. S., Kosmyna, B., Fulop, D., & Rogler, L. E. (2017) · Gene Expression · doi:10.3727/105221616x693891 · Cited by 23
Metadata
- Authors
- Sanderson, N., Factor, V, Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., Roberts, A. B., Sporn, M. B., & Thorgeirsson, S. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-03-28
- Volume
- 92
- Issue
- 7
- Pages
- 2572-2576
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2082401103
- Cited by
- 671
- References
- 25
- FWCI
- 20.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.